We have located links that may give you full text access.
[ALC/AMC Value and Prognosis in Patients with Primary Follicular Lymphoma Treated with R-CHOP Chemotherapy].
Zhongguo Shi Yan Xue Ye Xue za Zhi 2018 Februrary
OBJECTIVE: To study the value of absolute lymphocyte count/absolute monocyte count (ALC/AMC) and its effect on prognosis in patients with primary follicular lymphoma treated with rituximab combined with cyclophosphamide + doxorubicin + vincristine + prednisone (R-CHOP) chemotherapy.
METHODS: Seventy patients with primary follicular lymphomawere in our hospital were treated with R-CHOP chemotherapy, the ALC/AMC value of peripheral blood was recorded, and the prognosis was assessed by the international prognostic index.
RESULTS: According to the scores of the international prognostic index, 30 (42.86%) patients with score of 0-1 were enrolled in low-risk group, 21(30.00%), patients with score of 2 were enrolled in as the intermediate-risk group and 19 patients(27.14%) with score of 3-5 were enrolled in high-risk group. In the 3 group, the total effective rate of the low-risk group was the highest (95.24%), second was the intermediate-risk group (86.67%) and the total effective rate of the high-risk group was the lowest (78.95%), which showed that the difference was statistically significant (P<0.05); the progression-free survival(PFS) rate of 3 years in the low risk group was the highest (90%), followed by the intermediate-risk group (76.19%), and the PFS rate of the high-risk group was the lowest (52.63%)(P<0.05). The total effective rate of ALC/AMC<4.7 group was significantly lower than that of ALC/AMC ≥4.7 group (68.63% vs 89.47%) (P<0.05), and the PFS rate of 3 years was lower than that of ALC/AMC≥4.7 group (70.59% vs 89.47%) (P<0.05). Multivariate analysis revealed that ALC/AMC value in the peripheral blood was an independent prognostic factor for patients with follicular lymphoma (P<0.05).
CONCLUSION: The value of ALC/AMC in the peripheral blood may be an important marker for evaluation of prognosis in patients with primary follicular lymphoma treated with R-CHOP chemotherapy, which helps to assess the patient' s immune and tumor microenvironment.
METHODS: Seventy patients with primary follicular lymphomawere in our hospital were treated with R-CHOP chemotherapy, the ALC/AMC value of peripheral blood was recorded, and the prognosis was assessed by the international prognostic index.
RESULTS: According to the scores of the international prognostic index, 30 (42.86%) patients with score of 0-1 were enrolled in low-risk group, 21(30.00%), patients with score of 2 were enrolled in as the intermediate-risk group and 19 patients(27.14%) with score of 3-5 were enrolled in high-risk group. In the 3 group, the total effective rate of the low-risk group was the highest (95.24%), second was the intermediate-risk group (86.67%) and the total effective rate of the high-risk group was the lowest (78.95%), which showed that the difference was statistically significant (P<0.05); the progression-free survival(PFS) rate of 3 years in the low risk group was the highest (90%), followed by the intermediate-risk group (76.19%), and the PFS rate of the high-risk group was the lowest (52.63%)(P<0.05). The total effective rate of ALC/AMC<4.7 group was significantly lower than that of ALC/AMC ≥4.7 group (68.63% vs 89.47%) (P<0.05), and the PFS rate of 3 years was lower than that of ALC/AMC≥4.7 group (70.59% vs 89.47%) (P<0.05). Multivariate analysis revealed that ALC/AMC value in the peripheral blood was an independent prognostic factor for patients with follicular lymphoma (P<0.05).
CONCLUSION: The value of ALC/AMC in the peripheral blood may be an important marker for evaluation of prognosis in patients with primary follicular lymphoma treated with R-CHOP chemotherapy, which helps to assess the patient' s immune and tumor microenvironment.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app